Publications by authors named "Meiying Duo"
Article Synopsis
- Mantle cell lymphoma (MCL) is a challenging blood cancer characterized by poor prognosis and high relapse rates, prompting ongoing research for better treatments.
- Bruton's Tyrosine Kinase (BTK) is a key player in the survival of malignant B cells and has become a focus for targeted therapies, with first-generation inhibitors like ibrutinib showing promise in clinical settings.
- Despite initial successes with BTK inhibitors, issues like limited duration of response and the development of drug resistance highlight the need for ongoing research and potential new treatment strategies for MCL.
